References
- Addington, D., Addington, J., & Maticka-Tyndale, E. (1993). Assessing depression in schizophrenia: The Calgary Depression Scale. British Journal of Psychiatry, 163(S22), 39–44. https://doi.org/https://doi.org/10.1192/S0007125000292581
- American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders: 4th edition (DSM IV) text revision (4th ed., Text revision ed.). American Psychiatric Association.
- Boks, M. P. M., Liddle, P. F., Burgerhof, J. G. M., Knegtering, R., & Bosch, R.-J. (2004). Neurological soft signs discriminating mood disorders from first episode schizophrenia. Acta Psychiatrica Scandinavica, 110(1), 29–35. https://doi.org/https://doi.org/10.1111/j.1600-0447.2004.00298.x
- Cannon-Spoor, H. E., Potkin, S. G., & Wyatt, R. J. (1982). Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin, 8(3), 470–484. https://doi.org/https://doi.org/10.1093/schbul/8.3.470
- Chakos, M. H., Alvir, J. M., Woerner, M. G., Koreen, A., Geisler, S., Mayerhoff, D., Sobel, S., Kane, J. M., Borenstein, M., & Lieberman, J. A. (1996). Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Archives of General Psychiatry, 53(4), 313–319. https://doi.org/https://doi.org/10.1001/archpsyc.1996.01830040049009
- Chouinard, G., & Margolese, H. C. (2005). Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophrenia Research, 76(2–3), 247–265. https://doi.org/https://doi.org/10.1016/j.schres.2005.02.013
- Cuesta, M. J., Sanchez-Torres, A. M., de Jalon, E. G., Campos, M. S., Ibanez, B., Moreno-Izco, L., & Peralta, V. (2014). Spontaneous Parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: A 6-month follow-up study. Schizophrenia Bulletin, 40(5), 1164–1173. https://doi.org/https://doi.org/10.1093/schbul/sbt125
- First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. (1996). Structured Clinical Interview for DSM-IV Axis I disorders, clinician version (SCID-IV). American Psychiatric Press.
- Gervin, M., Browne, S., Lane, A., Clarke, M., Waddington, J. L., Larkin, C., & O’Callaghan, E. (1998). Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: Baseline rate in a group of patients from an Irish catchment area. American Journal of Psychiatry, 155(9), 1202–1206. https://doi.org/https://doi.org/10.1176/ajp.155.9.1202
- Glazer, W. M., Morgenstern, H., & Doucette, J. (1994). Race and tardive dyskinesia among outpatients at a CMHC. Psychiatric Services, 45(1), 38–42. https://doi.org/https://doi.org/10.1176/ps.45.1.38
- Gunther, W., Gunther, R., Eich, F. X., & Eben, E. (1986). Psychomotor disturbances in psychiatric patients as a possible basis for new attempts at differential diagnosis and therapy. II. Cross validation study on schizophrenic patients: Persistence of a “psychotic motor syndrome” as possible evidence of an independent biological marker syndrome for schizophrenia. European Archives of Psychiatry and Neurological Sciences, 235(5), 301–308. https://doi.org/https://doi.org/10.1007/BF00515918
- Gureje, O., Nortje, G., Makanjuola, V., Oladeji, B. D., Seedat, S., & Jenkins, R. (2015). The role of global traditional and complementary systems of medicine in the treatment of mental health disorders. The Lancet Psychiatry, 2(2), 168–177. https://doi.org/https://doi.org/10.1016/S2215-0366(15)00013-9
- Guy, W. (1976). ECDEU assessment manual for psychopharmacology. United States Department of Health Education and Welfare.
- Honer, W. G., Kopala, L. C., & Rabinowitz, J. (2005). Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. Journal of Psychopharmacology, 19(3), 277–285. https://doi.org/https://doi.org/10.1177/0269881105051539
- Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276. https://doi.org/https://doi.org/10.1093/schbul/13.2.261
- Koning, J. P., Tenback, D. E., van Os, J., Aleman, A., Kahn, R. S., & van Harten, P. N. (2010). Dyskinesia and Parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: A meta-analysis. Schizophrenia Bulletin, 36(4), 723–731. https://doi.org/https://doi.org/10.1093/schbul/sbn146
- McCreadie, R. G., & Ohaeri, J. U. (1994). Movement disorder in never and minimally treated Nigerian schizophrenic patients. British Journal of Psychiatry, 164(2), 184–189. https://doi.org/https://doi.org/10.1192/bjp.164.2.184
- Morgenstern, H., & Glazer, W. M. (1993). Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications results of the Yale Tardive Dyskinesia Study. Archives of General Psychiatry, 50(9), 723–733. https://doi.org/https://doi.org/10.1001/archpsyc.1993.01820210057007
- National Institute for Health and Care Excellence. (2014). Psychosis and schizophrenia in adults. Retrieved from https://www.nice.org.uk
- Ojagbemi, A., Esan, O., Emsley, R., & Gureje, O. (2015). Motor sequencing abnormalities are the trait marking neurological soft signs of schizophrenia. Neuroscience Letters, 600, 226–231. https://doi.org/https://doi.org/10.1016/j.neulet.2015.06.028
- Ou, J.-J., Xu, Y., Chen, H.-H., Fan, X., Gao, K., Wang, J., Guo, X.-F., Wu, R.-R., & Zhao, J.-P. (2013). Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. Psychopharmacology, 225(3), 627–635. https://doi.org/https://doi.org/10.1007/s00213-012-2850-6
- Pappa, S., & Dazzan, P. (2009). Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: A systematic review. Psychological Medicine, 39(07), 1065–1076. https://doi.org/https://doi.org/10.1017/S0033291708004716
- Peralta, V., Campos, M. S., De Jalon, E. G., & Cuesta, M. J. (2010). Motor behavior abnormalities in drug-naive patients with schizophrenia spectrum disorders. Movement Disorders, 25(8), 1068–1076. https://doi.org/https://doi.org/10.1002/mds.23050
- Peralta, V., & Cuesta, M. J. (1999). Negative Parkinsonian, depressive and catatonic symptoms in schizophrenia: A conflict of paradigms revisited. Schizophrenia Research, 40(3), 245–253. https://doi.org/https://doi.org/10.1016/S0920-9964(99)00047-X
- Peralta, V., & Cuesta, M. J. (2010). The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naive nonaffective psychotic patients: A naturalistic study with haloperidol, risperidone, or olanzapine. Primary Care Companion to The Journal of Clinical Psychiatry, 12(2). https://doi.org/https://doi.org/10.4088/PCC.09m00799gry
- Reiter, P. J. (1926). Extrapyramidal motor disturbances in Dementia Praecox. Acta Psychiatrica Neurologica, 1, 281–310. https://doi.org/https://doi.org/10.1111/j.1600-0447.1926.tb11031.x
- Schooler, N., Rabinowitz, J., Davidson, M., Emsley, R., Harvey, P. D., Kopala, L., McGorry, P. D., Van Hove, I., Eerdekens, M., Swyzen, W., & De Smedt, G., Early Psychosis Global Working, G. (2005). Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. American Journal of Psychiatry, 162(5), 947–953. https://doi.org/https://doi.org/10.1176/appi.ajp.162.5.947
- Sethuraman, G., Taylor, C. C., Enerson, M., & Dunayevich, E. (2005). A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. Schizophrenia Research, 79(2–3), 337–340. https://doi.org/https://doi.org/10.1016/j.schres.2005.06.015
- Veerman, S. R. T., Schulte, P. F. J., & de Haan, L. (2017). Treatment for negative symptoms in schizophrenia: A comprehensive review. Drugs, 77(13), 1423–1459. https://doi.org/https://doi.org/10.1007/s40265-017-0789-y